Phase I clinical trial using a novel CCK 2 receptor-localizing radiolabelled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma - final results

Poster: "EANM 19 / EPS-077 / Phase I clinical trial using a novel CCK2 receptor-localizing radiolabelled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma - final results" by: "A. Hubalewska-Dydejczyk1, R. Mikolajczak2, C. Decristoforo3, P. Kolenc-Peitl4, P. A. Erba5, K. Zaletel4, H. Maecke6, T. Maina7, M. W. Konijnenberg8, P. Garnuszek2, M. Trofimiuk-Muldner9, E. Przybylik-Mazurek9, I. Virgolini3, M. de Jong8, A. C. Froberg8, C. Rangger3, G. Goebel3, L. Scarpa3, B. Glowa10, K. Skorkiewicz10, L. Lezaic4, B. Solnica9, D. Fedak9, P. Gaweda9, A. Sowa-Staszczak9, B. A. Nock7, D. Bergant4, S. Rep4, V. Lenda-Tracz10; 1Jagiellonian University, Endocrinology Dep, Nuclear Med. Unit, KRAKOW, POLAND, 2NCBJ POLATOM, Otwock-Swierk, POLAND, 3Medical University, Innsbruck, AUSTRIA, 4University Medical Center, Ljubljana, SLOVENIA, 5University of Pisa, Pisa, ITALY, 6University Medical Center, Freiburg, GERMANY, 7National Center for Scientific Research Demokritos, Athens, GREECE, 8Erasmus MC, Rotterdam, NETHERLANDS, 9Jagiellonian University, Krakow, POLAND, 10University Hospital, Krakow, POLAND"